1118 / 1835
IMRT in lymphoma RT
IMRT has been thought to be less useful and still not regarded as a
standard option in hematological malignancies because:
o
Lower prescribed doses, generally well below tolerance dose of
normal tissues
o
Fear of late effects secondary to low-dose exposure of larger
volumes of healthy tissues
o
Theoretical increased risk of geographic miss, as the dose gradients
are steeper around the target volumes